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HIV-exposed uninfected (HEU) infants experience increased overall mortality from infec-
tious causes when compared to HIV-unexposed uninfected (HU) infants. This is the case 
in both the resource-rich and resource-limited settings. Here, we explore the concept 
that specific types of infectious diseases that are more common among HEU infants 
could provide clues as to the potential underlying immunological abnormalities. The 
most commonly reported infections in HEU vs. HU infants are caused by encapsulated 
bacteria, suggesting the existence of a less effective humoral (antibody, complement) 
immune response. Decreased transplacental transfer of protective maternal antibodies 
has consistently been observed among HEU newborns, suggesting that this may indeed 
be one of the key drivers of their susceptibility to infections with encapsulated bacteria. 
Reassuringly, HEU humoral response to vaccination appears to be well conserved. While 
there appears to be an increase in overall incidence of acute viral infections, no specific 
pattern of acute viral infections has emerged; and although there is evidence of increased 
chronic viral infection from perinatal transmission of hepatitis C and cytomegalovirus, no 
data exist to suggest an increase in adverse outcomes. Thus, no firm conclusions about 
antiviral effector mechanisms can be drawn. However, the most unusual of reported 
infections among the HEU have been opportunistic infections, suggesting the possibility 
of underlying defects in CD4 helper T cells and overall immune regulatory function. 
This may relate to the observation that the immunological profile of HEUs indicates a 
more activated T cell profile as well as a more inflammatory innate immune response. 
However, both of these observations appear transient, marked in early infancy, but no 
longer evident later in life. The causes of these early-life changes in immune profiles are 
likely multifactorial and may be related to in utero exposure to HIV, but also to increased 
environmental exposure to pathogens from sicker household contacts, in  utero and 
postnatal antiretroviral drug exposure, and, in certain circumstances, differences in 
mode of feeding. The relative importance of each of these factors will be important to 
delineate in an attempt to identify those HEU at highest risk of adverse outcomes for 
targeted interventions.
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TAbLe 1 | Mortality among HeU vs. HU infants.
Setting HeU (n) HU (n)
Marinda et al. (13) Zimbabwe 9.2% (3135) 2.9% (9210)
Shapiro et al. (9) Botswana 6.7% (534) 1.7% (137)
Brahmbhatt et al. (10) Uganda 16.5% (269) 12.8% (3183)
Van Der Loeff et al. (8) Gambia 14% (64) 8% (448)
Taha et al. (21) Malawi 4.6% (439) 3.6% (108)
Sutcliffe et al. (12) Zambia 5% (108) 1% (211)
Chilongozi et al. (14) Multisite Africa 7.2% (302) 4.8% (1429)
Kelly et al. (17) Botswana 12.5% (64) 2.6% (153)
Landes et al. (15) Malawi 18.7% (173) 4.3% (214)
Ajibola et al. (16) Botswana 5.1% (453) 1.8% (457)
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bACKGROUND
Due to successful interventions to prevent mother-to-child 
transmission (PMTCT) of HIV, the risk of HIV transmission in 
resource-rich settings has been reduced to <1% (1). The success-
ful scale-up of PMTCT programs in low- and middle-income 
countries is leading to transmission rates approaching those 
seen in resource-rich settings and means that, worldwide, HIV-
exposed uninfected (HEU) infants represent a growing propor-
tion of the pediatric population. In certain HIV-endemic nations, 
HEU infants represent nearly 30% of the newborn population (2). 
While this decrease in vertical transmission of HIV represents 
a tremendous achievement, it is not without consequence, for, 
while these infants are not infected with HIV, they are affected 
by the virus and by the treatments given during pregnancy to 
prevent transmission (3).
The first cohorts that followed HEU children longitudinally 
have reported increased morbidity and mortality when compared 
to HIV-unexposed uninfected (HU) children, and specifically, 
increased severity of infectious diseases (reviewed by Slogrove 
et  al. in this Research Topic) (4, 5). In certain HIV-endemic 
countries with high prevalence of maternal HIV infection, it is 
estimated that over half of all childhood mortality in the first 
24  months of life may be due to HIV exposure (6). While the 
cause of this increased morbidity and mortality from infectious 
diseases among HEU infants is likely to be multifactorial, encom-
passing environmental, maternal, and health systems factors, 
the increased burden of infections seen among them raises the 
question of whether immune alterations may contribute to their 
increased susceptibility to disease. To date, a number of studies 
have shown evidence of various immunological abnormalities 
among HEU children (7), with alterations in both humoral and 
cell-mediated immunity (CMI) reported. It is hypothesized that 
these immunological changes may result from a combination of 
factors whereby the in utero environment of HIV-infected moth-
ers uniquely shapes their infant’s immune system, leading to an 
increased susceptibility to infectious diseases.
In view of the number of recent reports of infectious diseases 
among HEU children, the main objective of this review is to probe 
the existing data regarding the infectious pathogens observed 
in HEU infants, and their association to specific alterations in 
immune defense mechanisms, in an effort to better understand 
the increased susceptibility to infectious disease observed in this 
vulnerable population.
PART 1: CLiNiCAL FiNDiNGS AMONG HeU 
iNFANTS
Rates of Mortality among HeU infants
Beginning as early as 2003, the first cohorts to follow HEU 
children reported increased morbidity and mortality when 
compared to HU children (8). While the overall mortality rate in 
studies of HEU infants varies (ranging from 4.6 to 18.7% in the 
African setting, see Table 1) (7–16), the majority of studies have 
demonstrated increased mortality among HEU vs. HU infants 
across all settings, with mortality rates ranging from twice to 
fourfold above HU controls. Moreover, it appears that the cause 
of mortality, when investigated, is predominantly infectious. 
Specifically, studies in Botswana and Durban, South Africa, 
demonstrated higher rates of treatment failure in HEU infants 
diagnosed with pneumonia when compared to HU infants, with 
higher associated mortality (17, 18). HEU infants also suffered 
higher mortality from invasive pneumococcal disease (IPD) 
when compared to HU infants (33.7 vs. 22.4%) in a South African 
surveillance study (19) and increased mortality from lower res-
piratory tract infection (OR: 2.1, CI: 1.1–3.8) compared to HU 
infants (20). The emerging pattern is one of increased mortality 
from infectious diseases, and primarily from respiratory illness, 
among HEU infants.
Rates of Hospitalization/illness
In addition to increased overall mortality, recent studies have 
reported increased rates of all-cause hospitalization among HEU 
children when compared to HU children. Among 825 HEU 
children in the European Collaborative Study, 25% had been 
hospitalized in the first 2  years of life, with a reported rate of 
0.5 per 5 child-years (22). A study of 736 HEU infants in India 
found that 35% of HEU infants had been hospitalized within the 
first year of life, with an overall rate in infancy of 906 per 1000 
person-years (PY) (23). Again in that study, the majority (56%) 
of hospitalizations were due to infectious diseases (primary three 
causes included acute gastroenteritis 18.6%, sepsis/meningitis 
11.5%, and pneumonia 6.6%). This pattern of high incidence of 
hospitalization has also been observed in resource-rich settings. 
In Belgium, the incidence of severe infections was estimated at 
16.8% HEU infant years (24). In France, the risk of serious infec-
tions during the first year of life was estimated at 9.3% in HEU 
children (25). In a Canadian cohort, a higher rate of hospitaliza-
tion was seen among infants born to mothers with detectable 
viral load at delivery (31 per 100 PY) compared to mothers with 
undetectable viral load (10 per 100 PY) (p = 0.02) (26). In addi-
tion to hospitalization, increased health-care utilization among 
HEU infants has been described. In one of the largest longitudinal 
studies of HEU children in Zimbabwe, sick clinic visits were 1.2 
times more likely among HEU compared to HU children (27). 
Again, where documented, the overwhelming cause of health-
care visits/hospitalizations was due to infectious diseases. In a 
small prospective South African cohort, HEU infants were 3.6 
times more likely to develop a severe infection requiring hospi-
talization in their first year of life compared to HU controls (28). 
In a laboratory-based surveillance study in South Africa, HEU 
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infants were found to have twice the rate of hospitalization from 
IPD compared to HU infants (19). A prospective South African 
cohort study of children undergoing surgery observed sig-
nificantly higher rates of postsurgical complications among HEU 
compared to HU controls (23.7 vs. 5.7%); these were most often 
surgical site complications (impaired wound healing, infection, 
breakdown) or sepsis (29). In a large series from the Caribbean, 
HEU infants were found to have three times the incidence of 
neonatal infections compared to HU infants (26 per 1000 vs. 8.1 
per 1000) (30). Taken together, these studies indicate an increased 
rate of health-care visits, hospitalization, and severe infections in 
the first 2 years of life among HEU infants across all settings.
Specific infectious Diagnosis  
among HeU Children
Amidst the reports of increased morbidity, mortality, and 
hospitalization among HEU children, a number of studies have 
documented the causative pathogens, whose presence may sug-
gest specific areas of immune dysfunction (Table 2).
Fungal Infections
The most striking of infectious findings among HEU infants 
have been case series reporting Pneumocystis jirovecii pneumo-
nia (PJP) in infancy. The earliest of these were two case reports 
in Texas of HEU infants diagnosed with PJP at <2  months of 
age (31). Subsequently, PJP was confirmed among three HEU 
infants in a cohort of infants with severe pneumonia in Durban, 
South Africa (18). A study of infants hospitalized with hypoxic 
pneumonia in Cape Town reported PJP in 5 of the 34 who were 
HEU (33), while a separate study also in South Africa found PJP 
in 3 of 8 hospitalized HEU infants with severe pneumonia (32). A 
large prospective cohort study in Zimbabwe (n = 3185) studying 
health outcomes in HEU infants found an increased incidence 
of oral candidiasis in HEU vs. HU infants (34). Fungal infec-
tions, and specifically PJP, are typically considered opportunistic 
infections seen in immune compromised individuals. Their pres-
ence is strongly suggestive of immunodeficiency and warrants 
thorough investigation of T lymphocyte function and number in 
particular (41, 42).
Bacterial Infections
Bacterial infections have also featured prominently in reports of 
increased morbidity and hospitalization of HEU infants. Among 
clinical cohorts with microbiologically confirmed diagnoses, the 
clearest difference in infectious pathogens between HEU and HU 
infants are infections caused by encapsulated bacteria. A cross-
sectional study of infants with IPD in South Africa found a higher 
rate among HEU infants (33–88 per 100,000) compared to HU 
infants (18–28 per 100,000) (19). A Belgian study found that rates 
of IPD were fourfold higher among HEU infants compared to the 
general infant population (24). The same cohort also reported 
rates of group B Streptococcus (GBS) infection that were 13-fold 
higher in HEU infants compared to the general infant population 
(35). A hospital-based surveillance study in Soweto, South Africa, 
reported a 2.25-fold greater incidence of GBS in HEU compared 
to HU infants (36). In a large French cohort documenting severe 
infections among HEU infants during their first year of life, 
encapsulated bacteria (Haemophilus influenzae and Streptococcus 
pneumoniae) were the causative organism for 56.7% of confirmed 
bacterial infections (25). Susceptibility to encapsulated organisms 
may be due to defects in humoral immunity, complement defi-
ciency, or asplenia. Antibody-mediated, or -humoral, immunity 
is particularly important in the defense against infection caused 
by polysaccharide-encapsulated bacteria. Infants are transiently 
protected from these infections through transplacental transfer 
of maternal antibody, until their own humoral responses develop. 
An increase in infections by such organisms in infancy would 
be suggestive of decreased maternal antibody protection, while 
an increased susceptibility to such infections after the age of 
two would be more suggestive of defects in humoral immunity 
(43). In addition to humoral immunity, another key defense 
against bacterial pathogens is the complement system, part of the 
innate immune response. Individuals with specific complement 
deficiency would have increased susceptibility to infection with 
these bacterial pathogens (44, 45). These infections would also 
be more common in individuals with congenital or acquired 
asplenia, such as those with underlying hemoglobinopathies (46).
Due to the high burden of tuberculosis (TB) coinfection 
among HIV-infected patients, a higher incidence of TB among 
HIV-infected pregnant women and subsequently their exposed 
infants would be expected when compared to HU controls. To 
date, however, there have been no comparative studies on the true 
incidence or severity of TB disease in HEU vs. HU infants. In 
a prospective randomized control trial of isoniazid prophylaxis 
among HIV-infected and HEU children in a South African cohort, 
the incidence of pulmonary TB was fourfold higher among HEU 
when compared to a historical control group of HUs in South 
Africa (37). Difficulties in obtaining microbiological confirmation 
of TB disease may potentially have resulted in an underreporting 
of TB-related deaths, likely classified as pneumonia. If  indeed 
an increased incidence of severe TB disease is confirmed among 
HEU infants, this may be related to increased exposure to TB, 
or it may further suggest a defect in T cell function or number, 
and/or defects in interferon gamma (INF-γ) receptor pathways or 
tumor necrosis factor (TNF) signaling pathways (47, 48), which 
are necessary for control of mycobacterial infections.
Viral Infections
The frequency and severity of viral infections among the HEU 
infants has been more difficult to characterize, likely due to 
technical challenges and the costs associated with viral pathogen 
testing in resource-limited settings. While upper respiratory 
tract infections (URTIs) and LRTIs have been more frequently 
reported (30), only one study to date has characterized specific 
respiratory viral pathogens seen in HEU vs. HU children. In a 
South African surveillance study, there was an increased risk of 
all-cause LRTI (OR: 1.4, CI: 1.3–1.5) among HEU vs. HU, with 
increased incidence of respiratory syncytial virus (RSV), rhino-
virus, enterovirus, adenovirus, and Human metapneumovirus-
associated LRTI, but no difference in incidence of influenza (IRR: 
1.2, CI: 0.8–1.8) (20). Among the common acute life-threatening 
systemic viral infections of childhood, there are surprisingly no 
reports of increased frequency of varicella or measles infections in 
the HEU children. CMI is the key mechanism of defense against 
TAbLe 2 | infectious diagnosis and immune correlates among HeU infants.
Country Findings infant immune correlates Maternal immune correlates Reference
Fungal infections
Pneumocystis 
jirovecii
United States 
1997
Two cases PJP Transient decrease in absolute 
CD4 cell count (cases 1 and 
2). Normal immunoglobulin and 
lymphocyte proliferation (case 2)
Maternal CD4 counts 27 and  
47 cells/mm3
Heresi 
et al. (31)
Pneumocystis 
jirovecii
South Africa 
2001–2002
Three cases of PJP Not assessed Not assessed McNally 
et al. (18)
Pneumocystis 
jirovecii
South Africa  
2010
Three cases of PJP 1 case persistently low CD4 
count, 1 case transiently low, 1 
case normal. Immunoglobulin 
levels normal (2), not assessed (1)
None WHO stage 3 or 4 disease. 
Median CD4 count 538 cells/mm3
Slogrove 
et al. (32)
Pneumocystis 
jirovecii
South Africa 
2006–2008
Five cases of PJP Not assessed Not assessed Morrow 
et al. (33)
Candida Zimbabwe 
1997–2000
Increased incidence of oral 
candidiasis
Not assessed Increased incidence in infants of 
mothers with CD4 <200 cells/mm3 
(IR 3.91) vs. <800 cells/mm3 (IR 1.91)
Evans et al. 
(34)
bacterial infections
Streptococcus 
pneumoniae
South Africa 
2009–2013
Increased rate of invasive 
pneumococcal disease HEU 
vs. HU (33–88 per 100,000 vs. 
18–28 per 100,000)
Not assessed Not assessed Von 
Mollendorf 
et al. (19)
Streptococcus 
pneumoniae
Belgium 
1985–2006
Fourfold increase in rate in HEU 
vs. HU
Not yet available, studies 
underway
Twofold increase in frequency of severe 
infections with maternal CD4 count 
<200 (not statistically significant)
Adler et al. 
(24)
Group B 
Streptococcus
Belgium 
2001–2008
13-fold increase in rate of 
invasive disease in HEU vs. HU
Increased total leukopenia at start 
of sepsis compared to HU infants
In one of six infants, maternal CD4 
count <350 cells/mm3
Epalza 
et al. (35)
Group B 
Streptococcus
South Africa 
2004–2007
2.25-fold increase in incidence 
of invasive disease in HEU vs. 
HU
Not assessed Increased risk of early onset sepsis 
among infants of mothers CD4  
<200 vs. >350 cells/mm3
Cutland 
et al. (36)
Haemophilus 
influenzae, 
Streptococcus 
pneumoniae
France 
2002–2010
Encapsulated organisms were 
the cause of 56.7% of bacterial 
infections in infancy
No association between infant 
CD4 count at birth and risk of 
infection
Association between lower maternal 
CD4 count and serious bacterial, but 
not viral infections
Taron-
Brocard 
et al. (25)
Mycobacterium 
tuberculosis
South Africa, 
Botswana 
2004–2008
Incidence of pulmonary TB 
fourfold higher HEU than 
historical controls
Not assessed Not assessed Madhi 
et al. (37)
viral infections
Respiratory 
(RSV, Rhinovirus, 
Enterovirus, 
Adenovirus)
South Africa 
2010–2013
Increased incidence causing 
LRTI among HEU vs. HU
Not assessed Not assessed Cohen 
et al. (20)
Hepatitis B Malawi 
2004–2009
11.9 and 12.8% HBV infection 
in infants of women HbsAg or 
HBV DNA positive
Not assessed Not assessed Chasela 
et al. (38)
Cytomegalovirus United States 
1998–2002
Increased rate of congenital 
CMV infection (3.6%) vs. 
general population (1%)
Not assessed Increased risk of congenital or early 
postnatal CMV with maternal  
CD4 <200 vs. >200 cells/mm3
Frederick 
et al. (39)
Epstein–Barr 
virus
Kenya 
1999–2003
Early acquisition of EBV 
infection
Not assessed Maternal prenatal CD4 <20% and 
viral load >4.5-log RNA, associated 
with increased rate of EBV acquisition
Slyker 
et al. (40)
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viral pathogens. If indeed higher rates of acute viral illness among 
HEU were confirmed, this could be due to disorders of CMI, 
which would include both quantitative or qualitative deficiencies 
in T cells, or natural killer cells (NK cells), or antigen-presenting 
cells (APCs) (49, 50). At the same time, decreased transfer of 
maternal antibodies and deficiencies in innate immune func-
tion, through limitations in cytokine production or cytokine 
responsiveness, would also contribute to increased susceptibility 
to acute viral infections.
Among chronic viral diseases, the reported rates of perinatal 
Hepatitis C transmission is consistently higher among HEU 
than in the general population of HU infants (2.5-fold), likely 
due to increased maternal viremia and viral shedding (51). 
However, there is no evidence of increased perinatal hepatitis 
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B virus (HBV) transmission (38), potentially due to increasing 
use of antiretroviral regimens with specific activity against HBV 
during pregnancy (tenofovir and emtricitabine). Finally, among 
latent infections, HIV-infected women have a much higher rate 
of transmission of cytomegalovirus (CMV), with a reported 
prevalence of congenital CMV of 1.5–7% among HEU infants, 
compared to only 1% among HU infants (39, 52, 53). The role of 
Epstein–Barr virus (EBV) infections in the morbidity and mor-
tality of HEU infants is less clear. While primary EBV infection 
has been shown to occur early in HEU infants (mean time to 
primary infection 11 months) (40), there have been no studies 
comparing EBV acquisition and pathogenesis between HEU and 
HU infants. Effector CD4 T cells are important for the control of 
these chronic viral pathogens that infect cells for at least part of 
their life cycle and could be a factor in increased susceptibility to 
and symptoms associated with congenital herpes virus infections, 
such as CMV (54).
PART ii: iMMUNe ALTeRATiONS 
AMONG HeU CHiLDReN
Adaptive immune Responses
T Lymphocytes
The initial reports of PJP pneumonia – typically an opportunistic 
pathogen in individuals with defects in CMI – among HEU 
infants first prompted investigation into the T cell response of 
HEU infants. In five of the above cases of PJP where CD4 T cell 
number was assessed, three reported transient decreases in abso-
lute CD4 T cell number with full recovery, one with persistently 
low CD4 count, and one case with normal CD4 count (31, 32). In 
one case, lymphocyte proliferation was assessed and was found 
normal (31).
Overall, phenotypic differences in T cell populations have 
been detected in multiple studies of HEU infants. A Brazilian 
study reported a neonatal immune profile skewed away from a 
naive phenotype, with decreased proportions of naive CD4 and 
CD8 T cells and increased proportions of central memory CD4 
and CD8 T cells in HEU compared to HU children (55). HEU 
infants have also been shown to have higher T cell expression 
of activation marker CD38 (56). Similarly, Clerici et al. reported 
reduced proportions of naive CD4 and CD8 T cells and increased 
proportions of memory CD4 and CD8 T cells, combined with 
increased percentages of activated CD8 T cells in HEU compared 
to HU newborns (57). Lower absolute CD4 T cell counts have 
been reported among HEU infants exposed to higher levels of 
maternal viremia in utero (58), lower maternal CD4 T cell count 
(59), and those exposed to any antiretrovirals (60), suggesting that 
there may be individual differences in absolute CD4 T cell number 
within the HEU population. Taken together, these reports suggest 
in utero priming of T lymphocytes in HEU newborns. Whether 
this priming is related to exposure to specific antigens crossing 
the placenta or to non-antigen-specific activation remains to be 
determined, as are any direct clinical implications.
Functional differences in HEU lymphocyte populations have 
also been detected, although they have proven more inconsistent 
and therefore difficult to interpret. Cord blood mononuclear cells 
of HEU infants displayed reduced production of IL-4 and IL-7 
and increased production of IL-10 and INF-γ compared to HU 
infants (61). However, these findings contrast those of an earlier 
study that reported significantly higher concentrations of serum 
IL-7 in HEU newborns, as well as older children, compared to their 
age-matched HU controls (57). There is a lack of data to explain 
this discrepancy, although in the former study, all HIV-positive 
mothers had low or undetectable viral load, while maternal viral 
load information was not available for the later study. Increased 
IL-10 production in response to phytohemagglutin (PHA) 
stimulation of cord blood leukocytes in HEU infants compared 
to HU was previously described in a South African cohort that 
took place in the pre-ARV era (62). This is in contrast to reports 
of reduced levels of IL-10 in the cord blood mononuclear cells of 
HEU infants whose mothers did not control viral load (63).
Functional responses to antigenic stimuli are also difficult 
to interpret, given the limited available data thus far. A study 
from South Africa reported that stimulation with Staphylococcus 
Enterotoxin B (SEB) and Bacille Calmette–Guérin (BCG) induced 
increases in CD4 and CD8 T cell proliferation; however, prolif-
eration was comparable between HEU and HU in response to 
stimulation with Bordetella pertussis antigen (64). An investiga-
tion into markers of activation and cytokine expression at 3 and 
12 months of age in response to tetanus toxoid in a Kenyan cohort 
did not detect a difference in TNF-α, IFN-γ, or IL-2 at 3 months 
of age (65).
In short, while reports of PJP pneumonia are suggestive 
of immune deficiency affecting T lymphocytes, the possible 
mechanisms are not yet well understood. While the induction 
of memory T cells has been consistently observed, it remains 
unclear whether in utero HIV exposure influences the magnitude 
or quality of T cell responses to pathogens or vaccines.
B Lymphocytes and Antibodies
The increased incidence of GBS and pneumococcal sepsis in 
infancy among HEU infants across multiple settings suggests 
increased susceptibility to bacterial pathogens in the first year of 
life. The most unequivocal difference in immune status reported 
among HEU and HU infants is the decreased transfer of mater-
nal antibodies to HIV-exposed newborns. Actively transported 
maternal IgG are the source of virtually all the IgG subclasses 
detected in the fetus and neonates, and these maternally derived 
levels fall rapidly after birth, reaching a nadir of approximately 
4000 mg/dL in term infants at 3–4 months of age (66). A number 
of studies have reported reduced levels of maternally derived 
antibodies to vaccine- or pathogen-specific antigens, including 
tetanus (67–70), measles (71, 72), Haemophilus influenzae B 
(Hib), pertussis and pneumococcus (69), and GBS in HEU as 
compared to HU newborns (Abu Raya et al. in review) (73). These 
reduced levels can be related to lower levels of specific antibodies 
in HIV-infected women, reduced placental transfer, or a combi-
nation of these. A Brazilian study found reduced levels of anti-
bodies to tetanus, measles, and pneumococcus in HEU neonates, 
despite maternal antibody levels that were comparable between 
HIV-positive and HIV-negative mothers (74). Bashir et  al. 
reported that HIV-positive women were 16.27 times more likely 
than HIV-negative women to be seronegative for anti-tetanus 
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antibody, while their infants were 33.75 times more likely to be 
seronegative (67). They further concluded that HIV-positive 
mothers were 4.91 times more likely to have poorly efficient 
transplacental transfer of antibodies. A study in South Africa 
reported lower levels of antibodies to Hib and pneumococcus 
in HIV-infected women, but no significant difference for tetanus 
or pertussis (69). Levels of anti-GBS antibodies were found to be 
reduced in HIV-infected women compared to uninfected women 
in two separate South African cohorts (73, 75). Unfortunately, the 
studies documenting lower transplacental transfer of maternal 
antibody to HEU infants have not directly examined the clinical 
outcomes of these infants; thus, any association between lower 
antibody levels and increased risk of sepsis from encapsulated 
organisms remains a hypothesis. However, studies have shown 
an association between maternal immune suppression (lower 
CD4 T cell count) and increased incidence of bacterial infections 
(24, 25, 36), suggesting that maternal immune suppression, lead-
ing to decreased transplacental transfer of protective antibodies, 
represents a likely mechanism.
While studies are underway looking at humoral responses 
to vaccines in HEU infants, thus far, these appear to be intact. 
A  few  studies indicated that antibody responses to pertussis 
and pneumococcus vaccines were actually higher in HEU as 
compared to HU infants, whereas the responses to tetanus and 
Hib vaccines were similar in the two groups (68, 69). The higher 
vaccine response may be related to a lower inhibition by the 
reduced levels of maternal antibodies (76).
innate immune Responses
Concurrent with decreased protection from maternal antibodies, 
differences in early-life innate immune development between 
HEU and HU infants may predispose them to increased infec-
tious disease morbidity, most commonly from viral infections 
(76). Innate immunity orchestrates the initial, non-specific 
response to pathogens, while shaping future adaptive responses 
to prevent or clear infections (3) While there is very limited data 
on innate immune development among HEU infants, studies 
have shown that the first year of life is a period of rapid change 
in innate immune response, with differences in the developing 
immune profile of HEU vs. HU infants.
While well-known phenomena of neonatal innate immune 
development, such as deficiency in α and β defensins or comple-
ment pathways, may contribute to increased susceptibility to 
fungal infections in infancy, these may be magnified in HEU 
infants through additional mechanisms. Comparisons of early-
life innate immunity in HEU and HU infants have demonstrated 
altered secretion of immune-mediating cytokines, with decreased 
IL-12 production in HEU vs. HU infants (77). Upregulation of 
cell surface receptors, such as increased MHCII expression, has 
been identified on unstimulated HEU APCs, relative to HU APCs 
(78). Functional comparison of NK cell activity at 1 month of age 
also demonstrated an increase of an intermediate NK phenotype 
for activation and perforin expression in HEU vs. HU, which 
was no longer significant by 1  year of age (79). Studies have 
also demonstrated a hyperinflammatory innate immune profile 
among HEUs and a proinflammatory innate immune response 
to stimulation with pathogen-associated molecular patterns 
(PAMPs) early in life. In a prospective study of innate immune 
development in the first year of life among HEUs, HEU APCs 
responded more strongly than HU in both the proportion of 
responder cells, and quantity of cytokine produced per cell, with a 
strong pattern of hyperresponsive polyfunctional monocytes and 
classical dendritic cells. The majority of differences were observed 
between 2 weeks and 6 months of age and were largely in response 
to bacterial PAMPs (80).
Different ethnic groups (with varied genetic backgrounds 
by extrapolation) can exhibit varied innate immune responses 
(81, 82). More specifically, TLR polymorphisms are associated 
with heterogeneity of innate responses (83). Therefore, in com-
paring HEU and HU immune development, it is essential to 
consider any differences in the ethnic distribution of populations 
where HIV is more vs. less prevalent. Future studies are needed 
to examine relative contributions of potential etiological factors 
to changes in innate immune ontogeny, and how those changes 
in immune development contribute to early-life susceptibility 
to infectious disease (75). For example, there has been recent 
focus on vaccine-induced non-specific innate immunity that 
exhibits adaptive-like characteristics, called “trained immunity” 
(84). BCG vaccination-induced trained immunity is shown 
to be associated with drastic reductions (17–37%) in LRTIs 
(85); however, the effects on innate immune cells appear to 
be transient. Epigenetic programing of monocytes by H3K4 
trimethylation were detected very early in the first year but 
diminished by 12 months post-BCG exposure (86). Similar to 
BCG-induced transient changes in innate immunity, altered 
intra uterine or early-life exposures may transiently impact 
HEU innate immunity early in life. We do not know if the 
hyperinflammatory state in HEU infants early in life negatively 
impacts non-specific “trained immunity” or specific vaccine-
induced immunity.
PART iii: UNDeRLYiNG CAUSeS OF 
ALTeReD iMMUNiTY
Maternal Health Status
The cause of the immunological changes seen among the HEU 
is not clear, though is likely multifactorial (Figure  1). First, 
maternal health status and viral control is strongly suspected 
to play a role. Multiple studies have observed an association 
between maternal viral load and infant immune parameters. 
A   prospective study  of HEU infants in Mozambique reported 
that despite similar median levels of naive, memory, and activated 
CD4 and CD8 T cell counts between 1-month-old HEU and HU 
infants, HEU infants born to mothers with a high viral load 
had reduced numbers of naive CD8 and increased numbers of 
memory CD8 T cells compared to infants born to mothers with 
a lower viral load (87). Differences related to maternal viral load 
have also been observed at the functional level. CBMCs of HEU 
infants, whose mothers had a controlled viral load, produced 
higher levels of the anti-inflammatory cytokine IL-10 and were 
functionally more similar to the HU control group, while infants 
born to mothers with detectable viral load had reduced IL-10 and 
significantly higher levels of TNF-α (63). Overall, lower maternal 
FiGURe 1 | Mechanisms contributing to poor health and survival in HeU infants.
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immune status has been shown to be associated with adverse 
clinical outcomes in their infants. A birth cohort in Zambia 
found that infants of mothers with CD4 counts <350 cells/mm3 
had a higher risk of hospitalization and mortality compared to 
infants of mothers with CD4 >350 cells/mm3 (59). A European 
cohort found that lower maternal CD4 count was associated with 
increased risk of serious bacterial, but not viral infections (35); 
however, increased risk of congenital and early postnatal CMV 
infection was seen in infants of mothers with CD4 counts <200 
vs. >200  cells/mm3 in a US cohort (39). In the Zvitambo trial 
reporting on health outcomes among HEU, the incidence of oral 
candidiasis was significantly increased among HEU infants born 
to mothers with CD4 counts <200 vs. >800 cells/mm3 (OR: 3.91 
vs. 1.91, p < 0.05) (34). Finally, in the two cases of HEU infants 
with PCP reported in Texas, the maternal CD4 counts at time of 
delivery were 27 and 47 cells/mm3, respectively (29).
Combination Antiretroviral Therapy
Combination antiretroviral therapy (cART) during pregnancy, 
while essential and life-saving, may paradoxically be a contribut-
ing factor to immunological changes seen in the HEU infants. The 
recommended treatment for all HIV-infected pregnant women 
includes two nucleoside reverse transcriptase inhibitors (NRTIs) 
along with a protease inhibitor, for the duration of pregnancy 
(88). NRTI drugs induce to different degrees mitochondrial 
dysfunction, due to their affinity for mitochondrial gamma 
DNA polymerase. This affinity can interfere with mitochondrial 
replication, resulting in mitochondrial DNA (mt DNA) deple-
tion and dysfunction. Aberrant histological morphology of 
mitochondria, mt DNA mutations, alterations in mitochondrial 
DNA levels in cord blood mononuclear cells, aneuploidy in cord 
blood cells, downregulation of select pattern recognition receptor 
genes, and altered secretion of soluble markers of inflammation 
(89–92) have all been described in both non-human primates 
and neonates exposed in utero to NRTIs (93). In the Woman and 
Infants Transmission (WITS) cohort study from North America, 
HEU infants who had had exposure to ARVs had lower total 
lymphocyte counts and absolute CD4 counts at 0–2 months of 
age, and again at 6–25 months of age, when compared to HEU 
who were not exposed to ARVS. Maternal CD4 counts were also 
significantly associated with lower infant CD4 counts in both 
groups (60). In the French Perinatal Cohort study, any ARV 
exposure was associated with lower CD4 and CD8 T cell counts 
in these infants, and again maternal CD4 counts <500  cells/
mm3 were associated with lower infant CD4 counts (94). World 
Health Organization (WHO) guidelines recommend exclusive 
breast-feeding and infant ARV prophylaxis for the duration of 
breast-feeding (95), though little is known to date about effects 
of long-term ARV exposure (i.e., during the entire duration of 
breast-feeding) on the infant’s developing immune system.
Feeding Patterns
The role of breast-feeding in HEU infant susceptibility to infec-
tious diseases is not clear. On the one hand, studies have consist-
ently shown a benefit to exclusive breast-feeding vs. formula or 
mixed feeding in resource-limited settings in preventing infant 
morbidity and mortality (96–98). This is likely due to increased 
transfer of maternal immune factors, including antibodies, and 
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reduced risk of infectious exposure from potentially contami-
nated water sources associated with formula feeding (9, 21, 99). 
On the other hand, in the context of maternal HIV infection, 
breast-feeding presents an increased risk of HIV transmission 
from mother to infant (100–102). Finding the balance between 
reducing risk of HIV transmission, while preserving the benefits 
of breast-feeding, is a programmatic challenge (103). In response 
to the accumulated data on morbidity related to infant feeding 
practices, particularly in the context of ARV therapy, WHO 
guidelines on HIV and infant feeding practices were updated in 
2010. They remain consistent with the guidelines of 2006, which 
recommended exclusive breast-feeding for HIV-infected mothers 
unless replacement feeding is acceptable, feasible, affordable, sus-
tainable, and safe, in which case avoidance of all breast-feeding by 
HIV-infected mothers is recommended (104). This has resulted 
in different practices in resource-rich and resource-limited set-
tings, complicating our understanding of how this may impact 
the developing infant’s immune system.
In resource-rich settings where exclusive formula feeding is 
recommended, infants may be at risk for infectious diseases in 
infancy due to reduced protective maternal antibodies (105, 106). 
However, this may be counterbalanced by expanded immuniza-
tion coverage in these settings and, more importantly, increased 
access to health care and health services, which can mitigate this 
risk. In resource-limited settings, however, the recommendations 
for exclusive breast-feeding likely protect infants from infectious 
diseases-associated morbidity and mortality. Breast milk contains 
compounds that modulate PRR-mediated immune responses, 
including immunoglobulins, cytokines, antimicrobial proteins/
peptides, nucleotides, and oligosaccharides (107–110). Breast 
milk immune composition is impacted by maternal nutritional 
status, exclusivity and duration of breast-feeding, and maternal 
or infant infections (110, 111), and maternal HIV-seropositivity 
does not appear to be an independent determinant of altered 
breast milk immune composition or quality (112). To counterbal-
ance the increased risk of HIV acquisition during breast-feeding, 
the WHO recommends that all mothers remain on ARV therapy 
during the duration of breast-feeding (Option B+) and recom-
mends daily antiretroviral prophylaxis for the infants in order to 
reduce the transmission of HIV. The protection provided through 
breast-feeding must be balanced against the risks associated with 
increased ARV exposure, and, most importantly, postnatal HIV 
acquisition.
environmental Factors
Finally, an important factor in the shaping of the innate immune 
system is the environment (and associated pathogens) to which a 
person is exposed. HEU infants may also be exposed to a differ-
ent variety of pathogens in the household, as immunosuppressed 
HIV-positive individual(s) in the home carry a heavier burden 
of disease, and potentially more opportunistic pathogens (13). 
HEU infants may therefore have a different innate imprint from 
HU infants in the same setting due to increased microbial expo-
sure in early life. As an example, increased lipopolysaccharide 
has been identified in the serum of infants who lack access to 
running water in the household (113), which can lead to chronic 
inflammation in the gastrointestinal system, and a gut that is 
more prone to bacterial translocation. Increased exposure to 
lipopolysaccharide can lead to immune tolerance of endotoxin; 
indeed, lacking access to running water correlates positively 
with expression of IL-10 in childhood (114). Determining if 
the transient diminished capacity to contain infection is medi-
ated at least in part by non-specific environmental exposure is 
an important next step toward understanding morbidity and 
mortality in HEU infants.
PART iv: CONCLUSiON AND FUTURe 
DiReCTiONS
Summary
Across multiple cohort settings, HEU infants have been shown 
to have increased morbidity and mortality when compared to 
HU infants, and specifically higher rates of infectious diseases. 
While the studies reporting on microbiological diagnosis have 
been predominantly from South Africa, Belgium, and France, 
the overall reports of morbidity and mortality from infectious 
diseases have spanned different treatment eras (prior to and after 
widespread ARV availability) and geographical regions, sug-
gesting that this is most likely related to infrastructure, research 
capacity, and expertise in these settings, rather than a specific 
geographical cluster of disease. The most commonly reported 
infections include invasive bacterial infections with encapsulated 
organisms, upper and lower respiratory tract infections, and 
diarrheal illnesses, most often within the first year of life, with 
additional case reports of PJP pneumonia. Of note, there have 
not been reports of increased prevalence of vaccine preventable 
diseases, including measles or disseminated TB, often common 
contributors to childhood mortality in resource-limited settings. 
Taken together, these findings suggest that there is likely an 
immunological basis for the increased susceptibility of HEU to 
infectious diseases in infancy.
The most consistently demonstrated difference in immune 
status between HEU and HU infants has been decreased maternal 
antibody transfer, which likely explains the increased susceptibil-
ity to encapsulated organisms in early life. However, there have 
been no direct studies correlating lower protective antibody 
levels and risk of, e.g., sepsis among HEU infants. At the same 
time, additional mechanisms that could explain this susceptibil-
ity to encapsulated organisms have not yet been studied, includ-
ing complement deficiencies and splenic function, which may 
increase their susceptibility to these bacterial pathogens. Given 
that the susceptibility to these infections is predominantly seen 
during infancy and not later in life, this suggests that the humoral 
antibody response of HEU infants is preserved. The mechanisms 
that may underlie their susceptibility to opportunistic pathogens 
(PJP), chronic viral infections (CMV, HCV), and possibly acute 
viral infections (upper and lower respiratory tract infections, 
viral gastroenteritis), is less clear. There is some evidence of 
decreases in T lymphocyte number and function; however, these 
changes appear to be limited to select HEU infants, such as those 
exposed to high levels of maternal viral load or specific antiret-
roviral regimens. HEU infants have been shown to have a more 
experienced immune profile and innate immune responses, but 
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it is not known how this may lead to increased susceptibility to 
disease.
Future Directions
In this review, we have attempted to correlate the reported clini-
cal with the immunological findings among HEU infants. From 
this review, it becomes clear that there remains a significant 
knowledge gap in understanding the immunological basis for 
the increased susceptibility to infectious diseases in HEU vs. 
HU infants. While a number of clinical, epidemiological, and 
surveillance-based studies have reported on infectious outcomes, 
these same studies have not been able to extensively study the 
immune profile of affected infants, likely due to the challenges 
in obtaining specimens and conducting immunological assays in 
resource-limited settings. At the same time, while a number of 
detailed immunological assays on a small cohort of HEU chil-
dren (predominantly in resource-rich settings) have been done, 
there are few correlates to clinical outcomes, given the relatively 
small number of HEUs that become severely ill in these settings. 
Future work needs to be directed at directly correlating infec-
tious disease outcomes to immunological findings among HEU 
infants. This would best be achieved through prospective cohort 
studies where detailed microbiological and immunological data 
would be collected in a sufficiently large number of HEU infants, 
with concurrent collection of detailed data on maternal immune 
status, in  utero and postnatal drug exposure, and feeding pat-
terns, in order to identify potential confounders and the relative 
contribution of each of these factors.
implications
With an estimated 1.3 million HEU children born annually, their 
increased susceptibility to infectious diseases and associated 
mortality in infancy suggests that where resources are limited, 
targeted interventions may be necessary for those at highest risk 
for adverse outcomes, such as those HEU infants born to moth-
ers with advanced disease, highest immune suppression, and 
uncontrolled viremia. While standard of care in HEU follow-
up varies across settings, specific health interventions could 
be envisioned. These include expanded vaccination coverage 
(including maternal immunization) to target the most identi-
fied causes of illness (pneumococcal vaccine, meningococcal 
vaccine, rotavirus vaccine), improved nutritional support and 
micronutrient supplementation, and potentially, antimicrobial 
prophylaxis during the first 6 months of life. A number of studies 
are currently underway to determine the efficacy of such inter-
ventions, including on the efficacy of antibiotic prophylaxis, the 
immunogenicity, and efficacy of additional vaccines in the HEU 
population.
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